Apricus Biosciences products
Vitaros (alprostadil topical cream)
Indication: Erectile dysfunction
Status: Approved and launched in Europe and Canada; Apricus retained U.S. rights but faced FDA rejections and CMC/safety challenges; ex-U.S. rights sold to partners
RayVa (PGE₁ cream)
Indication: Raynaud’s phenomenon (circulatory disorder affecting hands/feet)
Status: Completed Phase 2a clinical trial
Femprox (PGE₁ cream)
Indication: Female sexual interest/arousal disorder
Status: Development candidate (proof-of-concept explored)
NexACT technology
Description: Proprietary permeation enhancer enabling rapid transdermal absorption of active compounds like prostaglandin E₁ for topical delivery
Applications: Core to Vitaros, RayVa, Femprox formulations
No comments:
Post a Comment